Lund University is celebrating 350 years. Read more on lunduniversity.lu.se

Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer

Author:
  • Vasundhra Kashyap
  • Shafqat Ahmad
  • Emeli M. Nilsson
  • Leszek Helczynski
  • Sinead Kenna
  • Jenny L Persson
  • Lorraine J. Gudas
  • Nigel P. Mongan
Publishing year: 2013
Language: English
Pages: 555-566
Publication/Series: Molecular Oncology
Volume: 7
Issue: 3
Document type: Journal article
Publisher: Elsevier

Abstract english

Recurrent prostate cancer remains a major clinical challenge. The lysine specific demethylase-1 (LSD1/KDM1A), together with the JmjC domain-containing JMJD2A and JMJD2C proteins, have emerged as critical regulators of histone lysine methylation. The LSD1-JMJD2 complex functions as a transcriptional co-regulator of hormone activated androgen and estrogen receptors at specific gene promoters. LSD1 also regulates DNA methylation and p53 function. LSD1 is overexpressed in numerous cancers including prostate cancer through an unknown mechanism. We investigated expression of the LSD1 and JMJD2A in malignant human prostate specimens. We correlated LSD1 and JMJD2A expression with known mediators of prostate cancer progression: VEGF-A and cyclin A1. We show that elevated expression of LSD1, but not JMJD2A, correlates with prostate cancer recurrence and with increased VEGF-A expression. We show that functional depletion of LSD1 expression using siRNA in prostate cancer cells decreases VEGF-A and blocks androgen induced VEGF-A, PSA and Tmprss2 expression. We demonstrate that pharmacological inhibition of LSD1 reduces proliferation of both androgen dependent (LnCaP) and independent cell lines (LnCaP: C42, PC3). We show a direct mechanistic link between LSD1 overexpression and increased activity of pro-angiogenic pathways. New therapies targeting LSD1 activity should be useful in the treatment of hormone dependent and independent prostate cancer. (C) 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Keywords

  • Cancer and Oncology
  • Epigenetic
  • Biomarker
  • Urological
  • Angiogenesis
  • Chromatin
  • Recurrence

Other

Published
  • Genetic and Molecular Epidemiology
  • Pathology, Malmö
  • Experimental Cancer Research, Malmö
  • ISSN: 1574-7891
E-mail: shafqat.ahmad [at] med.lu.se

Doctoral student

Genetic and Molecular Epidemiology

+46 40 39 11 49

+46 70 429 23 54

CRC 60-12-021b

33

Lund University Diabetes Centre, CRC, SUS Malmö, Entrance 72, House 91:12. SE-205 02 Malmö. Telephone: +46 40 39 10 00